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Hip and knee arthroplasty are two of the most common operations 
performed worldwide.[1] In the past decade, the occurrence of 
these surgical procedures has increased dramatically in step with 
the expansion and ageing of the world population. Technological 
advances and improvements in prosthetic design have also resulted 
in more indications and increased use.[2] Hip replacement surgery 
has increased by 30% over the past two decades, while it is estimated 
that the demand for knee replacement surgery will increase fourfold 
by 2030.[3,4] Neck of femur (NoF) fractures are common emergency 
conditions in the geriatric population, and despite declines in 
incidence rates in certain populations, the worldwide number is 
also expected to increase fourfold by 2050.[5] With reported 1-year 
mortality ranging between 12% and 37%, this is the most expensive 
fracture to treat, as compared with other fractures, more patients die 
during hospitalisation, or within 1 month of sustaining the injury.[5,6]
Arthroplasty patients comprise a large proportion of individuals 
at risk of cardiac complications, as many of these patients are of 
advanced age, have one or more other cardiac risk factors, and could 
additionally suffer from the physiological stress associated with an 
NoF fracture.[7,8] Risk factors include uncontrolled hypertension, 
ischaemic heart disease (IHD), diabetes, renal disease, advanced age 
(>60 years), heart failure, arrhythmias such as atrial fibrillation (AF), 
smoking, obesity, high cholesterol and poor nutritional status.[6,9-11]
Total hip and knee arthroplasty are classified as major surgeries 
that carry an increased risk of cardiac events perioperatively.[12] In 
2015, Smith et al.[1] reported that the most common cause of death 
(affecting 7 out of 10 patients) following NoF fracture was myocardial 
infarction (MI).[1]
Myocardial injury after non-cardiac surgery (MINS) is a silent 
event that occurs within 30 days after non-cardiac surgery.[13,14] It is 
thought to be a stress-induced ischaemia resulting from a myocardial 
oxygen supply and demand mismatch.[15,16] Unfortunately up to 80% 
of these MIs are underdiagnosed,[17,18] as the classic symptoms such 
as chest pain may be atypical or even absent.[19] Because the mortality 
is reported to be similar to conventional MIs,[20-22] an aggressive 
diagnostic and therapeutic approach is needed.
The diagnosis of MINS relies heavily on cardiac biomarkers[15] such 
as a new high-sensitivity troponin T assay (hs-cTnT), which is the 
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Background. Patients undergoing arthroplasty may have comorbidities that put them at risk of myocardial injury after non-cardiac surgery 
(MINS). MINS, a new clinical concept that has a different pathophysiology from conventional myocardial infarction, is related to a supply-
demand mismatch ischaemia in the perioperative setting. MINS is often a silent event, and the diagnosis relies on cardiac biomarker testing 
such as troponin T. The incidence is estimated at 40%, with a fourfold increase in morbidity and mortality risk 1 year post surgery.
Objectives. To determine the prevalence of postoperative troponin leak in a single-centre arthroplasty unit in patients with various cardiac 
risk factors undergoing hip or knee arthroplasty and investigate the differences in troponin T levels between comorbidities and different 
types of arthroplasty, i.e. total hip replacement (THR), total knee replacement (TKR) and neck of femur (NoF) fracture hip replacement.
Methods. A prospective, cross-sectional study of patients with one or more cardiac risk factors undergoing replacement surgery was 
conducted from October 2017 to April 2018. Troponin levels of all included patients were recorded on days 1 and 3 post surgery using a 
high-sensitivity cardiac troponin T assay (Roche hs-cTnT). A level of >15 ng/L is considered abnormal and termed a positive troponin leak, 
while >100 ng/L is considered suspected acute coronary syndrome (ACS).
Results. One hundred and sixty patients (n=66 THR, n=55 NoF hip replacement, n=39 TKR) were included. Sixty-eight patients (42%) 
had a positive troponin leak, and in 6 of these cases ACS was suspected. The highest prevalence of troponin leak was recorded in patients 
undergoing NoF hip replacement (62%), followed by TKR (46%) and then THR (24%). Sixty-two patients (38%) had positive troponin 
levels on day 1 and 53 patients (33%) had positive levels on day 3. Important patient cardiac risk factors were identified in the presence 
of a positive troponin leak, with ischaemic heart disease, hypertension, diabetes, renal disease, age >65 years and atrial fibrillation being 
statistically most likely.
Conclusions. Postoperative troponin surveillance is an inexpensive and reliable way to identify patients at risk of MINS and subsequently 
enhance early detection, medical optimisation and referral strategies. Simple interventions may improve outcomes and contribute to lower 
ACS rates and the timeous prevention of other complications. The prevalence of MINS in orthopaedic-specific patients in South Africa (SA) 
and other resource-constrained developing countries is unknown. Our finding of 42% positive troponin leaks raises awareness of this issue, 
and we recommend routine postoperative troponin surveillance for all arthroplasty units in SA.
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preferred biomarker in the diagnosis of MI,[23,24] as well as exclusion 
of known non-ischaemic causes of perioperative troponin elevation 
such as sepsis and burns.[16,24,25]
Perioperative troponin surveillance is a simple and cost-effective 
method[26] and of vital importance in diagnosing MINS.[13,27] The test 
also provides important prognostic information[19,28] when identifying 
patients at risk of a fatal outcome.[27-30]
Preventive strategies, medical optimisation and simple inter-
ventions, such as aspirin and statins, may improve outcome and 
survival.[13,17,31] It is important to note, however, that none of these 
strategies has focused solely on the orthopaedic population.[19] 
Under-appreciation of the extent of MINS, especially in elderly and 
cardiac patients undergoing arthroplasty, is therefore evident.
There are currently limited published data on the prevalence of 
MINS in orthopaedic-specific patients in South Africa (SA), and 
perioperative measurement of troponin levels is not considered 
standard protocol for patients undergoing arthroplasty.[16,32] In 
addition, there is currently insufficient information to successfully 
compare patient comorbidities in different arthroplasty procedures.
We hypothesise that there may be an underdiagnosis of MINS, 
specifically in the domain of arthroplasty, and establishing a statistical 
significance in the prevalence rate could raise awareness and, along 
with the provision of early optimal medical intervention, reduce 
morbidity and mortality.[16,33]
Objectives
The primary objective was to determine the prevalence of 
postoperative troponin leak in a single-centre arthroplasty unit in 
patients with different cardiac risk factors undergoing hip or knee 
arthroplasty. A secondary objective was to investigate the differences 
in troponin T levels between various comorbidities and different 
types of arthroplasty, i.e. total hip replacement (THR), total knee 
replacement (TKR) and NoF hip replacement.
Methods
Study design
A prospective observational study was conducted including all 
patients undergoing knee and hip arthroplasty at Tygerberg Hospital, 
a tertiary academic institution in Cape Town, SA. Ethical approval 
(ref no. S17/02/042) and hospital clearance for the study were granted 
by the health research ethics committees of Stellenbosch University 
and Tygerberg Hospital, respectively. The study was registered with 
the National Health Research Database (ref. no. WC_201803_017).
Participants
Potential participants for the study were recruited over a period of 
6 months from October 2017 to April 2018.
All patients admitted to the arthroplasty unit for joint replacement 
surgery who met the inclusion criteria were invited to participate in 
the study. Table 1 shows that patients eligible for the study: (i) were 
undergoing either primary elective knee or hip arthroplasty or non-
elective emergency arthroplasty for NoF fractures; (ii) were aged 
≥40 years or older; (iii) had one or more known cardiac risk factors 
(including but not limited to hypertension, IHD, smoking, diabetes, 
renal disease, obesity, high cholesterol, poor diet, excessive alcohol 
consumption and/or age ≥65 years); and (iv) had received either 
regional and/or general anaesthesia.[9,10,16,19] Patients who presented 
with sepsis and those with incomplete data on cardiac risk factors 
were excluded from the study (Table 1).
Study procedures
Patients were admitted as per the normal standard hospital protocol. 
General characteristics (including age, presence of comorbidities 
and potential cardiac risk factors) were recorded from history and 
hospital charts. Five of these risk factors are referred to as the ‘big five’ 
because of their known association with a high risk of myocardial 
injury.[5,6,9-11,34] These five risk factors are IHD, diabetes, renal disease, 
age >65 years and AF.
Written informed consent was obtained on admission and patients 
were also provided with a patient information leaflet. If the patient 
was unable to understand the process, a next of kin or legal guardian 
signed the consent on their behalf. An interpreter assisted with 
translation if needed.
A single blood sample (2 mL) was collected (i) on day 1 (at least 
12 hours postoperatively) and (ii) on day 3 postoperatively. These 
samples were then used to measure the serum troponin T levels of 
all included patients. This was done using a Roche 4th-generation 
Elecsys hs-cTnT assay. All results were recorded by the principal 
investigator. All test procedures were performed while the patients 
were still in hospital. Patients enrolled between 12 and 24 hours after 
surgery had blood samples drawn immediately once consent had 
been obtained, and testing continued as per the study protocol.
An hs-cTnT level of >15 ng/L was considered abnormal and 
termed a positive troponin leak,[20,24,34] while a cut-off level of 
>100  ng/L, a 50% change in an initial value of <53 ng/L, or a 20% 
change in an initial value between 53 and 100 ng/L were considered 
suspected acute coronary syndrome (ACS).[20,24,34,35] For the purposes 
of this study, ACS was clinically diagnosed by an increase in the 
referenced hs-cTnT values above the reference range accompanied by 
ischaemic symptoms, ischaemic electrocardiogram (ECG) changes or 
new pathological Q-waves.[36]
Patients continued to receive standard care from the arthroplasty 
unit, which included additional troponin tests and/or ECGs, if 
warranted. All patients were reviewed daily for symptoms 
of myocardial ischaemia such as chest pain, dyspnoea, nausea, 
pallor, discomfort in other areas of the body (abdomen, shoulder, 
jaw), altered neurology and hypotension.[37] If a patient met the 
requirements of a suspected ACS, they were managed and referred 
accordingly, as per the standard hospital protocol.
Statistical analysis
Data were analysed using STATISTICA version 13.2 (Statsoft Inc., 
USA). Data were tested for normality using the Kolmogorov-Smirnov 
test, and as the data were not normally distributed, data were 
expressed as medians and interquartile ranges (IQRs) or as numbers 
and percentages. Categorical data were expressed as frequencies and 
counts. Prevalence was determined as follows:
Table 1. Inclusion and exclusion criteria
Inclusion criteria
Age ≥40 years
 One or more known cardiac risk factors (age >65 years is an 
independent factor)
Elective knee or hip arthroplasty
Emergency NoF arthroplasty
Exclusion criteria 
Incomplete data regarding cardiac risk factors
Patients with sepsis
NoF = neck of femur.
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The effect of comorbidities on the risk 
of having a positive troponin T test was 
determined using Fisher’s exact test. 
A p-value <0.05 was considered significant.
Results
General characteristics
A total of 170 patients were screened for 
potential inclusion in the study, and 160 
were included (Fig. 1). The mean (standard 
deviation) age of the included participants 
was 66 (12) years, with 40% (n=64) male 
and 60% (n=96) female. Three individuals 
declined to participate in providing complete 
data for the study, and 7 did not meet the 
inclusion criteria.
A total of 66 patients (42%) underwent 
elective THR, 55 patients (34%) underwent 
NoF hip replacement, and 39 patients (24%) 
underwent elective TKR (Fig. 1).
The median (interquartile range (IQR)) 
time to surgery was 2 (1 - 4) days and the 
median time to discharge 4 (3 - 5.5) days. NoF 
patients waited slightly longer for surgery, 
with a median of 3 (2 - 6) days, and were 
discharged after a median of 4 (4 - 6) days 
(Table 2, Fig. 2).
Clinical characteristics
The overall prevalence of troponin leak 
was 42% (68/160) (Table 3), and 6 patients 
(4%) were identified with a suspected ACS 
according to the diagnostic criteria. Similar 
patterns were observed when the prevalence 
was stratified for sex (supplementary Table 1, 
available at http://www.samj.org.za/public/
sup/14133.docx).
A positive troponin leak was detected in 
39% of patients on day 1 following surgery, 
while 33% of patients tested positive on 
day 3 (Table 4). Not all patients who had 
tested positive on the first day (n=62) tested 
positive again on day 3 (n=14). Some of 
the patients who tested positive on day 3 
(n=53) had not tested positive on the first 
day (n=5). Similar patterns were observed 
when prevalence was stratified for sex 
(supplementary Table 2, http://www.samj.
org.za/public/sup/14133.docx).
Several cardiac risk factors and/or 
comorbidities were observed (Table  5). 
Patients identified with the ‘big five’ 
comorbidities IHD (odds ratio (OR) 4.7; 
95% confidence interval (CI) 1.9 - 11.4; 
p<0.001), renal disease (OR 17.6; 95% 
CI  2.2 - 139.8; p<0.001), age >65 years 
(OR  6.3; 95% CI   3.0   - 13.0; p<0.001) and 
AF (OR 13.9; 95% CI  1.7 - 112.5; p=0.002) 
were more likely to have a positive troponin 
test than those without these comorbidities. 
Other cardiac risk factors of interest included 
patients with hypertension, who showed 
an increased risk of a positive troponin test 
compared with patients who did not have 
hypertension (OR 23.3; 95% CI 1.5 - 4 332.5; 
p<0.001) (Table 5).
Discussion
Primary outcomes
The main finding of this study was that there 
was a 42.5% prevalence of postoperative 
troponin leak in patients with various 
Table 2. Summary of time to surgery and time to discharge
Days to surgery, median (IQR) Days to discharge, median (IQR)
All participants 2 (1 - 4) 4 (3 - 5.5)
NoF 3 (2 - 6) 4 (4 - 6)
THR 1 (1 - 2) 3 (3 - 4)
TKR 1 (1 - 2) 4 (3 - 6)
IQR = interquartile range; NoF = neck of femur fracture; THR = total hip replacement; TKR = total knee replacement.
Table 3. Overview of the prevalence of a troponin leak between different 
arthroplasty procedures
Positive leak, n (%) Negative leak, n (%)
All participants (N=160) 68 (42.5) 92 (57.5)
NoF (N=55) 34 (61.8) 21 (38.2)
THR (N=66) 16 (24.2) 50 (75.8)
TKR (N=39) 18 (46.2) 21 (53.8) 
NoF = neck of femur fracture; THR = total hip replacement; TKR = total knee replacement. 
Table 4. Overview of the prevalence of a troponin leak at day 1 and at day 3 post 
surgery
Positive leak, n (%) Negative leak, n (%)
Day 1 62 (38.8) 98 (61.3)
Day 3 53 (33.1) 107 (66.9)
Assessed for eligibility,
N=170   
Excluded, N=10 
•  Did not meet inclusion criteria, n=7 
   (<40 years n=2, did not undergo surgery n=5)
•  Incomplete data, n=3
Eligible,
n=160
TKR,
n=39
THR,
n=66
NoF fracture,
n=55
Fig. 1. Flowchart depicting patients enrolled in the study. (THR = total hip replacement; TKR = total 
knee replacement; NoF = neck of femur.)
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cardiac risk factors undergoing knee and hip arthroplasty. The need 
for arthroplasty procedures is on the increase in an ageing population. 
However, it is important to keep in mind that many patients who undergo 
these surgeries suffer from multiple comorbidities and are therefore 
susceptible to periopera tive cardiovascular complications. [9,10,16,19,22] 
Previous studies with varying numbers of participants have reported 
similar prevalence rates of troponin elevation.[20,25,38]
Dawson-Bowling et al.[38] in the UK investigated patients aged 
≥65  years who presented with an NoF fracture over a 4-month 
period. They reported that of the cohort of 129 patients, 39% showed 
a perioperative troponin rise.[38] Global data suggest that 8% of adults 
aged >45 years suffer from MINS, and SA studies yield similar event 
rates.[16,26] The local incidence of MINS in all orthopaedic patients is 
reported to be 10%, with an in-hospital mortality rate of 7.7%.[39-41]
When different types of arthroplasty procedures are compared, 
a higher preva lence of postoperative troponin leak is observed 
in patients with NoF fractures (67%) than in those admitted for 
elective surgery, including THR (24%) and TKR (46%). Previous 
studies on major non-cardiac surgery have not specifically focused 
on orthopaedic and/or arthroplasty patients, and the outcomes 
of patients undergoing different types of arthroplasty, whether 
elective or emergency surgery, have also not been compared.[7,17,25] 
In agreement with the findings presented in this study, NoF patients 
have previously been earmarked for special attention because they 
present with a higher incidence of postoperative troponin elevation 
(22 - 52%) than the elective population (0 - 9%). These patients are 
therefore a high-risk group in terms of MINS.[19]
The number of NoF fractures is expected to rise considerably by 
2050,[5] with a high mortality at 1 year.[19] Many of these patients die 
in hospital, or within 1 month after surgery.[5,6] In 2015, Smith et 
al.[1] reported that the most common cause of death following NoF 
fracture is MI, affecting 7 out of 10 patients. It is therefore important 
that potential MIs be detected early. This increased risk is further 
emphasised by the high prevalence of postoperative troponin leaks 
in NoF patients.
A further interesting observation from the present study was the 
time to surgery and time to discharge for each procedure. Although 
time to discharge was similar for the various procedures, on average 
NoF patients waited longer for surgery than individuals scheduled 
for elective surgery. As time to surgery is a critical factor in the 
outcome of an NoF fracture, we postulate that the increased waiting 
time for surgery may have contributed to the higher prevalence of 
postoperative troponin leaks.[42]
It has been reported that surgery within 24 - 48 hours leads to a 
reduction in 1-year mortality,[19,38] and it is therefore recommended 
that unnecessary preoperative investigations should be avoided. In 
the UK, >97% of patients who sustain an NoF fracture are operated 
on within 72 hours after injury.[42]
In a public health facility like our institution, reasons for delayed 
surgery are often multifactorial and include, but are not limited 
Table 5. Overview of the association of a positive troponin leak with different patient comorbidities
Comorbidity Prevalence (total N=160), n Positive leak, n (%) OR (95% CI) p-value
‘Big five’
IHD 29 21 (72.4) 4.7 (1.9 - 11.4) <0.001
Diabetes 21 11 (52.4) 1.6 (0.63 - 3.97) 0.352
Renal disease 12 11 (91.7) 17.6 (2.2 - 139.8) <0.001
Age >65 years 89 54 (60.7) 6.3 (3.0 - 13.0) <0.001
AF 10 9 (90.0) 13.9 (1.71 - 112.5) 0.002
Other
Hypertension 147 68 (46.3) 23.3 (1.5 - 4 332.5) <0.001
COPD 34 11 (32.4) 0.6 (0.26 - 1.28) 0.242
Obesity 18 6 (32.4) 0.5 (0.3 - 1.3) 0.334
Smoking 49 13 (26.5) 0.4 (0.2 - 0.9) 0.023
Hypercholesterolaemia 54 27 (50.0) 1.4 (0.7 - 2.8) 0.317
Poor nutritional status 12 5 (41.7) 1.1 (0.3 - 3.9) 1.000
OR = odds ratio; CI = confidence interval; IHD = ischaemic heart disease; AF = atrial fibrillation; COPD = chronic obstructive pulmonary disease.
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to, the following: (i) patient factors, such 
as uncontrolled medical comorbidities 
that may take a longer time to optimise 
prior to surgery; (ii) staff factors, including 
availability of trained surgical, anaesthetic 
and nursing staff; (iii) logistical factors, 
including available funding, theatre time, 
equipment and beds for postoperative high-
care monitoring; and (iv) the overwhelming 
number of patients with NoF fractures 
requiring surgery presenting to the faci-
lity. [43]
Six patients (4%) with a positive troponin 
elevation met the diagnostic criteria of a 
suspected ACS. These patients were generally 
older and had more than one cardiac 
risk factor. One patient required urgent 
resuscitation and was admitted to intensive 
care after an acute MI. We hypothesise that 
standard postoperative measures, which had 
already been initiated according to hospital 
protocol, in addition to early intervention 
could have contributed to an overall lower 
rate of progression to ACS in individuals 
identified with a troponin leak.
Secondary outcomes
Total hip and knee arthroplasty are classified 
as major surgeries and are known to be 
associated with a high risk of perioperative 
cardiac events.[12] In addition, many patients 
undergoing arthroplasty have multiple 
comorbidities and are therefore at increased 
risk of MINS. [8,10] There are also various 
surgical and anaesthetic perioperative factors 
associated with poor outcomes following hip 
and knee arthro plasty. [10]
Several cardiac comorbidities were 
identified, among them the ‘big five’. 
Previous studies identified these comor-
bidities as independent indicators of 
a fatal outcome following hip or knee 
arthroplasty. [5,9,10,16,34] Specifically, a history of 
IHD, renal disease, age >65 years, a history 
of AF and hypertension can increase the risk 
of troponin leak between 5- and 23-fold. 
Although the sample size of some of these 
comorbidities was small, and the results 
should therefore be interpreted with caution, 
being aware of these factors prior to surgery 
can help identify patients at risk. Surgical 
planning and the optimising of modifiable 
risk factors can ultimately prevent possible 
poor outcomes, especially in the case of 
elective surgery where there is sufficient 
time.[10,16,19]
It was interesting to note that diabetes 
was not identified as a risk factor for cardiac 
events in the present study, although the 
literature identifies it as such.[5,9,10,22] 
A  possible explanation is the small sample 
size of the subgroup of patients with 
diabetes and the fact that no information 
was recorded regarding control of the 
condition or whether or not insulin was 
being used. Similarly, smoking appeared 
to have a protective effect against troponin 
leak, a phenomenon highly contradictory 
to the literature.[9,10,44] Once again, the small 
sample size may be partly to blame for this 
surprising finding.
Additionally, no background information 
on smoking behaviour was collected, such as 
history and number of cigarettes smoked per 
day. In both instances these results, which 
are highly contradictory to global literature, 
should therefore be interpreted with great 
care and assessed and evaluated in future 
studies.
Troponin is most likely to be elevated on 
the first day after surgery (38%), and slightly 
less so on the third day (33%). Although 
most events will be identified on the first 
day, it was important to note that 5 patients 
only tested positive on day 3. These patients 
would have been missed if only a single 
test had been administered. Postoperative 
serum troponin levels demonstrate two 
peaks in elevation, the first at 18 - 24 hours 
and the second 3 days after surgery.[19] The 
VISION group demonstrated that troponin 
elevation during the first 3 days after non-
cardiac surgery was a major independent 
predictor of 30-day mortality.[17,25] The study 
also reported a substantial decline in MINS 
events by day 3. Although some events could 
statistically still present after this time, it is 
unlikely that any MINS events would have 
been missed.[25] Guidelines recommend the 
daily measuring of troponins for 48 - 72 
hours after surgery in high-risk patients.[32]
It is also important to note that while most 
patients develop an elevated troponin level 
within the first 24 hours after surgery, early 
MI could also result in a patient being more 
susceptible to a fatal outcome from non-
vascular complications such as pneumonia, 
which usually only develop on average 
6 days after surgery.[22,25]
Troponin surveillance must be executed 
proactively and not selectively, as we 
cannot reliably predict who will suffer 
a postoperative leak.[33] Up to 80% of 
postoperative MIs occur in patients with no 
more than one cardiac risk factor, and efforts 
to reduce incidence should therefore not be 
limited to high-risk patients with multiple 
comorbidities alone.[45]
Global implications
Postoperative troponin testing as standard 
practice is feasible and may help to 
improve the prognosis, risk stratification 
and management of patients.[46] At 
ZAR150 (USD10) per sample, this test is 
an inexpensive way to detect myocardial 
ischaemia and determine which patients are 
at risk of serious mortality.[23]
Oxygen
Optimise haemoglobin
Aspirin ± clopidogrel
Statin
Anticoagulation
± morphine, ± nitroglycerine
Haemodynamically stable
Beta-blockade
Haemodynamically unstable
Manage hypotension and dysrhythmias
Add beta-blocker when stable
Consider coronary angiogram if:
1. ST elevation
2. ST depression with recurrent symptoms and 
no contraindications to heparin
Fig. 3. Proposed algorithm for the management of patients with myocardial injury following non-
cardiac surgery[48] (permission for use obtained from the author and from the publisher).
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Based on 2011 private healthcare costs in South Africa, Torborg[26] 
conducted an economic analysis of perioperative troponin monitoring 
after non-cardiac surgery. The cost saving associated with routine 
troponin surveillance amounted to ZAR16 700 (~USD1 170) per 
event, and surveillance did not yield an unnecessary increase in 
expenditure associated with subsequent inappropriate coronary 
angiography.[26] This analysis was further comparable to another 
model, described by Lurati Buse et al.,[47] where the incremental cost 
of avoiding a missed MINS event was calculated at CAD1 632 (2015 
Canadian dollars).
From 1966 to 1986, pulmonary embolism (PE) and deep-vein 
thrombosis (DVT) were reported as having baseline mortality 
of 7% when associated with hip fractures.[32] The VISION study 
recorded a reduced mortality of 0.07% that can be attributed to 
DVT prophylaxis. [25,32] In the cases of DVT and PE, the proposed 
management of MINS advocates prevention and early intervention.
Observational data reported that 50% of patients have a 24-hour 
window period of sustained low troponin leak from ischaemic 
myocytes alone prior to cell death and further elevation.[16] Even after 
peak troponin, the median time to death varies from 9 to 12 days.[46] 
Intervention and medical optimisation can therefore be significantly 
improved during this window period.
Current data suggest that simple measures could improve outcomes, 
with attention given to an increase in postoperative monitoring, 
optimisation of myocardial oxygen balance via haemodynamic 
support, and correction of anaemia and electrolyte disturbances. [16] 
Biccard[33] introduced and modified a proposed algorithm that 
simplifies the management of patients with MINS according to 
haemodynamic stability and indicates when further intervention is 
needed (Fig. 3).
On the basis of recommendations published in the South African 
Medical Journal[16] and the South African Orthopaedic Journal,[32] this 
algorithm has also been adopted in our hospital division.
A therapeutic decision based on hs-cTnT needs to be considered 
carefully, as therapy could be harmful and increase the risk of 
bleeding. [14] The MANAGE study evaluated the impact of 
anticoagulation on perioperative vascular complications after MINS, 
and provisional results indicate improved outcomes.[48]
The POISE study ascertained that beta-blockers were useful 
in haemodynamically stable patients, but did not rule out the 
risk of stroke, hypotension, bradycardia and death.[45,49] Troponin 
surveillance and the use of simple therapies, such as aspirin and a 
statin for 30 days, may improve outcomes, with a 25% risk reduction 
in major cardiovascular complications.[26,48]
Study limitations
This study, although prospective, only included early postoperative 
prevalence and not preoperative troponin levels, which could be 
raised prior to surgery, especially in the NoF group. Preoperative 
testing could help to determine whether troponin elevation occurred 
before and/or after surgery and to quantify the extent of both.[15] This 
study also did not include any medium- and/or long-term follow-up 
of patients who experienced positive troponin leak/s to determine 
future implications.
The recording of patient cardiac risk factors included conditions 
sourced from patient history. However, the chronicity and/or severity 
of each condition, how well it was being controlled, and/or additional 
information detailing treatment were not specified.[44] Until further 
research has been done, all comorbidities should be managed on 
merit. In accordance with hospital protocol and in terms of Biccard’s 
proposed algorithm,[50] patients receive standard care. This study did 
not include discussion on the possible effects of an intervention or its 
contribution to the prevalence of a troponin leak, either on day 1 or 
day 3 after surgery.
Recommendations
Continued research into the pathophysiology of MINS is necessary, 
as data on its prevention and/or treatment are limited, especially 
in the areas of orthopaedic surgery and patients exhibiting various 
cardiac risk factors.
Troponin surveillance is a simple and inexpensive method that can 
be successfully employed in the recognition of MINS, allowing early 
medical optimisation of at-risk patients and prevention of serious 
complications. Future research should include long-term follow-up 
studies, perioperative comparisons, and additional implementations 
aimed at the prevention and/or management of MINS.
Conclusions
MINS, especially in conjunction with arthroplasty, is underdiagnosed 
and data on its prevalence in the SA population are limited. The 
reported 42% prevalence of postoperative troponin leak in our 
study population raises a new awareness regarding patients at risk 
of MINS, as well as the considerable health burden that it may pose. 
Additionally, the higher prevalence of postoperative troponin leak 
of 62% in NoF patients underscores the importance of troponin 
surveillance in this at-risk group.
We recommend that routine troponin surveillance be done in all 
arthroplasty units in SA in patients aged >40 years, those with one 
or more cardiac risk factors, and those who have sustained an NoF 
fracture.
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